Skip to main content
RT PhilipGardiner Plenary Abstract 839 Dr Schmukler Chicago Can we use MDHAQ multidimensional to ide

Philip Gardiner PhilipGardiner

8 years ago
Plenary Abstract 839: Dr Schmukler Chicago. Can we use MDHAQ (multi-dimensional) to identify FM? 84% agreement with 2011 FMS questionnaire - so the answer is Yes! (But what is the ‘gold std’?) @RheumNow #FMS #ACR18
RT WIRheum Checkpoint inhibitors
explosion of papers in 2018
New andor exacerbated arthritis myosi

D White WIRheum

8 years ago
Checkpoint inhibitors explosion of papers in 2018 New and/or exacerbated arthritis, myositis, lupus, sarcoidosis, sjogrens, vasculitis How to treat? - still unknown Year in review - clinical #ACR18 @RheumNow
RT KDAO2011 Risk for infection with TNFiMTX is NOT increased compared to triple DMARD Rx confirmed i

k dao KDAO2011

8 years ago
Risk for infection with TNFi+MTX is NOT increased compared to triple DMARD Rx confirmed in large claims database of commercial insurance #ACR18 @RheumNow abst#218 https://t.co/p25QwUX3ZN
RT KDAO2011 Plenary session High dose flu vaccine is safe and has better efficacy than standard flu

k dao KDAO2011

8 years ago
Plenary session: High dose flu vaccine is safe and has better efficacy than standard flu vaccine in our adult RA patients abst#837 @RheumNow #ACR18 https://t.co/MzAB6mUnHS
RT PhilipGardiner QampA Over half the GCA patients had LVV on PETCT note to self need to insist on m

Philip Gardiner PhilipGardiner

8 years ago
Q&A 'Over half the GCA patients had LVV+ on PET/CT' [note to self: need to insist on more PET/CT and push for Tocilizumb] #ACR18 @RheumNow #GCA
RT PhilipGardiner Abst 884 Jeff Sparks Predictors of ILD in RA in 1281 patients High disease activit

Philip Gardiner PhilipGardiner

8 years ago
Abst 884 Jeff Sparks. Predictors of ILD in #RA in 1281 patients: High disease activity, seropositivity - no surprises #ACR18 @RheumNow
RT PhilipGardiner Personal observation here over 25 years of practice Ive seen disease activity fall

Philip Gardiner PhilipGardiner

8 years ago
Personal observation here: over 25 years of practice I’ve seen disease activity fall and severe ILD become uncommon - but MTX use much more common. Time to rethink! #Acr18 #RA
RT PhilipGardiner Abst 2977 Dr Werth Lenabasam cannabinoid receptor type 2 CB2 agonist that activat

Philip Gardiner PhilipGardiner

8 years ago
Abst 2977 Dr Werth Lenabasam - cannabinoid receptor type 2 (CB2) agonist that activates resolution of innate immune responses - effective in reducing interferon beta and gamma in #Dermatomyositis skin biopsies #ACR18
RT WilliamShergy Whats in a name Gout by any other name may be better treated All hail Urate Crystal

William Shergy WilliamShergy

8 years ago
What’s in a name. Gout by any other name may be better treated. All hail Urate Crystal Arthritis#ACR18@RheumNow Abstract268 https://t.co/iGEENPJM85
RT WilliamShergy Lisa Sammaritano quoting a patient panel assisting in the development of Reproducti

William Shergy WilliamShergy

8 years ago
Lisa Sammaritano quoting a patient panel assisting in the development of Reproductive Guidelines for Rheumatology Patients. “My rheumatologist knows me better than my gynecologist.
RT DrPetryna 2789 Ph3 Apremilast for Behcets oral ulcers significantly lower number of OU P00015 amp

Olga Petryna DrPetryna

8 years ago
2789 Ph3 Apremilast for Behcet’s oral ulcers: significantly lower number of OU (P≤0.0015) &reduction in OU pain (P≤0.0035) vs PBO at wks 1-12. APR efficacy sustained at wk28: 62% pts achieved complete response of OU &70% relative reduction in OU pain from BL. #acr18 @rheumnow
Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
Dr. Cassie Calabrese: Checkpoint Inhibitors
Dr. Cassie Calabrese gives an overview of irAEs and checkpoint inhibitor therapy studies presented at the ACR/ARHP annual meeting in Chicago.
×